PT-141

Discovery and Development

PT-141 — generic name bremelanotide, brand name Vyleesi — is a synthetic cyclic heptapeptide derived from the endogenous hormone alpha-melanocyte-stimulating hormone (α-MSH). It originated from work at the University of Arizona on Melanotan II in the 1990s, where researchers noticed that the tanning-oriented parent compound also produced unexpected sexual arousal in male study participants. Pulling the sexual-arousal effect away from the tanning and appetite effects led to a truncated, cyclized analogue — first called PT-141, later licensed and developed by Palatin Technologies and AMAG Pharmaceuticals.

Bremelanotide was approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the second approved drug for that indication after flibanserin (Addyi). It is administered as a subcutaneous autoinjector, taken as needed at least 45 minutes before sexual activity.

Mechanism of Action

PT-141 acts centrally on the melanocortin system, with agonist activity at MC4R and MC3R receptors in the brain. Melanocortin signaling in the hypothalamus and mesolimbic circuits modulates sexual motivation — a pathway entirely separate from the vascular mechanism targeted by PDE5 inhibitors like sildenafil and tadalafil. PT-141 does not produce erection by peripheral vasodilation; it modulates the neural substrate of sexual desire and arousal.

This central mechanism is why PT-141 works in both sexes and why its use case in men overlaps with but does not duplicate PDE5 inhibitors: it can address arousal-driven dysfunction where the vascular pathway is already intact.

Clinical Evidence

FDA approval was supported by two pivotal Phase 3 trials — the RECONNECT program — which enrolled roughly 1,200 premenopausal women with HSDD. Over 24 weeks, bremelanotide produced statistically significant improvements in desire and reductions in distress compared with placebo, though absolute effect sizes were modest. Pre-approval development also included extensive studies in male erectile dysfunction; the male indication was not pursued to approval, in part because of the mature PDE5 market and safety-related titration constraints.

Off-label use in men for arousal-related sexual dysfunction is common in sexual-medicine practice, typically at lower doses than the 1.75 mg women's indication.

Practical Considerations

The approved dose is 1.75 mg subcutaneous at least 45 minutes before sexual activity, with a maximum of one dose per 24 hours and eight doses per month. Onset is typically 45–60 minutes, and the duration of the desire-enhancing effect is several hours. Unlike PDE5 inhibitors, food and alcohol do not meaningfully alter absorption.

A related compound, bremelanotide in its generic form, is the same molecule marketed outside the Vyleesi brand context — the distinction on this library is branding and sourcing rather than pharmacology. Users sometimes compare PT-141 to Melanotan II, which shares the melanocortin-agonist mechanism but is far less selective and carries additional pigmentation and safety concerns.

Safety and Regulatory Status

The most common adverse events in the RECONNECT trials were nausea (reported by roughly 40% of participants on active drug, driving most discontinuations), facial flushing, injection-site reactions, and headache. A transient increase in systolic blood pressure of roughly 6 mmHg occurs within a few hours post-dose, which is why uncontrolled hypertension and known cardiovascular disease are contraindications. Chronic frequent dosing has been associated with focal skin hyperpigmentation in a small subset of users.

PT-141 is FDA-approved as Vyleesi with a standard Rx label. Non-branded bremelanotide sold through research-chemical channels falls outside the regulated supply chain and carries the usual purity and quality caveats.

The Bottom Line

PT-141 is one of the few sexual-function peptides with genuine FDA approval and real Phase 3 data, and its central mechanism is meaningfully different from the established PDE5 class. The trade-off is a significant nausea burden and a modest average effect size — a good fit for the right patient, but not a universal sexual-function drug.